Abstract
Rationale: Aripiprazole (OPC-14597) elicits both dopamine D2 agonist and antagonist activities on dopaminergic neurons of the ventral tegmental area and nucleus accumbens neurons, respectively. However, the electrophysiological action of this drug on the striatal neurons is not clear. Objective: Therefore, the present electrophysiological study was performed to determine if aripiprazole modified the striatal neurons as a D2 receptor agonist or antagonist. Methods: Spikes elicited by stimulation of pars compacta of the substantia nigra (SN) were extracellularly recorded from the striatal neurons with a glass microelectrode attached along a seven- barreled micropipette. Each barrel was filled with aripiprazole, quinpirole (D2 receptor agonist), domperidone (D2 receptor antagonist), glutamate or 2 M NaCl. The drugs were microiontophoretically applied on the neurons being recorded. Results: The effects of aripiprazole on SN stimulation-induced spikes of striatal neurons that were inhibited by domperidone were examined. Microiontophoretic application of aripiprazole inhibited spikes elicited by SN stimulation in all 18 neurons tested in a dose-dependent manner. In addition, quinpirole-induced firing was inhibited by aripiprazole in all ten neurons tested. However, glutamate-induced spontaneous firing was not affected by aripiprazole in any of the ten neurons tested. Conclusions: These findings suggest that aripiprazole acts as a dopamine D2 receptor antagonist on striatal neurons receiving excitatory inputs from the SN.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 23 October 1998 / Final version: 3 May 1999
Rights and permissions
About this article
Cite this article
Matsubayashi, H., Amano, T. & Sasa, M. Inhibition by aripiprazole of dopaminergic inputs to striatal neurons from substantia nigra. Psychopharmacology 146, 139–143 (1999). https://doi.org/10.1007/s002130051099
Issue Date:
DOI: https://doi.org/10.1007/s002130051099